STOCK TITAN

Indaptus Therapeutics, Inc. - INDP STOCK NEWS

Welcome to our dedicated news page for Indaptus Therapeutics (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Indaptus Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Indaptus Therapeutics 's position in the market.

Rhea-AI Summary
Indaptus Therapeutics, Inc. announces interim data from the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The trial showed a favorable safety profile and stable disease in all four patients in the first cohort. The drug induced a broad expression of cytokines and chemokines associated with anti-tumor immune responses. Adverse events were generally tolerable and resolved within 30 minutes to three days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
-
Rhea-AI Summary
Indaptus Therapeutics, Inc. (Nasdaq: INDP) will present interim data from the Phase 1 INDP-D101 trial of its lead compound, Decoy20, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data showed activation of biomarkers associated with immune responses and expected adverse events. The full data will be presented at the conference on November 4.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
conferences clinical trial
-
Rhea-AI Summary
Indaptus Therapeutics, Inc. CEO to present corporate overview at LD Micro Main Event XVI on October 3. Webcast link available. One-on-one meetings scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
conferences
Rhea-AI Summary
Indaptus Therapeutics' CEO Jeffrey Meckler to present at Tribe Public's webinar on Immunotherapy Reimagined.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
none
-
Rhea-AI Summary
Indaptus announces dosing of second cohort in INDP-D101 trial with dose reduction based on positive pharmacodynamic effect seen in first cohort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
Rhea-AI Summary
Indaptus Therapeutics, Inc. CEO to present corporate overview at H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences
Indaptus Therapeutics, Inc.

Nasdaq:INDP

INDP Rankings

INDP Stock Data

17.30M
5.90M
30.87%
7.05%
1.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About INDP

the indaptus goal is simple: to cure disease with the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.